The TL;DR
Both are short peptide fragments derived from the C-terminal end of human growth hormone. Both isolate GH's fat-burning effects without triggering insulin resistance or IGF-1 elevation. They share the same core lipolytic mechanism — but they're not interchangeable.
- HGH Fragment 176-191 is the original, narrower-focus fragment. Pure fat loss play.
- AOD-9604 is a modified version (added tyrosine residue at the N-terminus) with enhanced receptor selectivity, FDA GRAS designation, and additional research-supported benefits for cartilage and insulin sensitivity.
Chapter 1: Understanding HGH Fragment 176-191
HGH Fragment 176-191 is a synthetic peptide representing amino acids 176–191 at the C-terminal end of human growth hormone. It was developed to isolate GH's lipolytic (fat-burning) effects without triggering insulin resistance or promoting cell growth.
Unlike full HGH, this fragment does not stimulate IGF-1 production or cause hyperglycemia — a key safety distinction.
Lipolysis Activation
Binds fat cell receptors to directly stimulate breakdown of stored triglycerides, particularly in visceral and subcutaneous adipose tissue.
Lipogenesis Inhibition
Actively blocks the formation of new fat cells, creating a dual mechanism that targets fat from both directions simultaneously.
Metabolic Boost
Elevates basal metabolic rate and enhances mitochondrial fat oxidation — even at rest — without a stimulant-like effect on the CNS.
Chapter 2: Understanding AOD-9604
AOD-9604 (Anti-Obesity Drug 9604) is a modified form of HGH Fragment 176-191 with an added tyrosine residue at the N-terminus. Originally developed by Monash University as an anti-obesity pharmaceutical, it shares the same core lipolytic mechanism but features enhanced stability and receptor-binding profile.
AOD-9604 received GRAS (Generally Recognized As Safe) status from the FDA in 2014 — a milestone that distinguishes it from most research peptides. This isn't full FDA drug approval, but it's a meaningful regulatory recognition of safety at typical research doses.
Enhanced Binding
The added tyrosine residue improves receptor selectivity, potentially increasing the efficiency of fat-cell targeting compared to the base fragment.
Cartilage & Repair
Research suggests AOD-9604 may support cartilage regeneration and joint tissue repair — benefits not observed in the base fragment.
Metabolic Regulation
Modulates metabolism through similar beta-3 adrenergic receptor pathways, with evidence of improved insulin sensitivity at therapeutic doses.
Chapter 3: Potential Benefits Side-by-Side
HGH Fragment 176-191
• Targeted fat loss, especially abdominal and visceral regions
• Increased energy expenditure and basal metabolic rate
• Preservation of lean muscle mass during caloric restriction
• No meaningful effect on blood glucose or IGF-1 levels
• May improve lipid profiles with sustained use
• Relatively fast onset — noticeable effects within 4–8 weeks
AOD-9604
• Targeted fat loss with potentially greater receptor selectivity
• Supports cartilage regeneration and joint health
• May improve insulin sensitivity and glucose metabolism
• Anti-inflammatory properties observed in preclinical models
• Favorable safety profile with FDA GRAS designation
• Broader therapeutic potential beyond weight management
Chapter 4: What the Research Actually Shows
Both peptides have demonstrated fat-loss activity in preclinical models. Human data is more limited — here's an honest assessment of the evidence.
- Animal studies: Consistently show 30–50% greater fat reduction vs. controls with both peptides.
- AOD-9604 Phase IIb trial (Monash University): Obese participants lost significantly more body fat vs. placebo over 12 weeks.
- HGH Frag 176-191: In vitro and rodent data confirm potent lipolytic action; direct human RCT data is sparse.
- Insulin safety: Neither peptide significantly altered blood glucose in human trials — a key differentiator from full HGH.
Most human evidence comes from small-scale or industry-funded trials. Independent large-scale RCTs are still needed to confirm long-term efficacy and safety in broader populations.
Chapter 5: Head-to-Head Comparison Table
HGH Fragment 176-191
Origin: C-terminal fragment of HGH (aa 176–191)
Primary mechanism: Beta-3 adrenergic receptor activation; direct lipolysis
Fat-loss efficacy: Strong preclinical; limited human RCTs
IGF-1 effect: None observed
Blood glucose: Neutral / slight improvement
Joint/tissue benefits: Not established
Regulatory status: Research peptide; not FDA approved
Half-life: ~30 minutes (subcutaneous)
Best suited for: Pure lipolysis / fat-loss focus
AOD-9604
Origin: Modified HGH fragment + tyrosine residue
Primary mechanism: Same mechanism, enhanced receptor selectivity
Fat-loss efficacy: Strong preclinical + Phase IIb human trial data
IGF-1 effect: None observed
Blood glucose: May improve insulin sensitivity
Joint/tissue benefits: Cartilage regeneration; anti-inflammatory
Regulatory status: FDA GRAS designation (2014)
Half-life: ~30–60 minutes (subcutaneous)
Best suited for: Fat loss + metabolic health + joint support
Chapter 6: Recommended Dosing Protocols
Both compounds require AOD water for reconstitution (acetic acid + benzyl alcohol + glycerol). Standard bacteriostatic water causes both peptides to gel, ruining the vial — this is a hard rule.
HGH Fragment 176-191 Protocol
Reconstitution: 2 mL AOD water
Standard dose: 500 mcg (20 units on a U-100 syringe)
Frequency: 1–2× daily
Timing: Fasted state — morning or pre-workout
Administration: Subcutaneous injection (abdomen preferred)
Cycle length: 8–12 weeks; 4-week break recommended
Max daily dose: 1,000 mcg (1 mg)
Storage: Refrigerated; use within 30 days of reconstitution
Best practice: Avoid carbohydrates 30 minutes pre/post injection
AOD-9604 Protocol
Reconstitution: 2 mL AOD water
Standard dose: 500 mcg (20 units on a U-100 syringe)
Frequency: 1× daily (some protocols use 2×)
Timing: Fasted state — morning preferred
Administration: Subcutaneous injection (abdomen preferred)
Cycle length: 12–16 weeks; 4–6 week break recommended
Max daily dose: 600 mcg
Storage: Refrigerated; use within 30 days of reconstitution
Note: Oral forms available but bioavailability is lower
These dosing guidelines reflect research protocols and anecdotal clinical use. Neither peptide is FDA-approved for human therapeutic use outside of controlled research settings. Always consult a qualified medical professional before any personal use.
Which One Should You Choose?
The honest answer depends on your specific goal:
- Pure fat loss, simplicity, lower cost: HGH Fragment 176-191. It's the original, cheaper, and well-characterized for the single job of lipolysis.
- Fat loss + joint support + insulin sensitivity: AOD-9604. The added receptor selectivity, regulatory designation, and broader benefit profile justify the modestly higher cost for most users.
- You have any joint or cartilage concern: AOD-9604 — the cartilage data isn't replicated in the base fragment.
- You're early in metabolic syndrome territory: AOD-9604 for the insulin-sensitivity signal.